Twenty-three market research firms that were covering Ariad Pharmaceuticals (NASDAQ:ARIA) stocks gave the stocks a consensus rating of ‘hold’ whereas three analyst firms have given the stocks a rating of ‘sell’. Moreover, the company’s stocks received a ‘hold’ rating from 11 other firms whereas 7 of the investment advisory firms gave the stocks a ‘buy’ rating. The company’s one year price target was set at $7.10.

On the last trade day, the company’ stocks saw a decrease of 2.31 percent in its prices, and the stocks closed at a price of $5.92. The company’s 52 week high is $23 whereas its 52 week low is $2.15, with a total market capitalization of $1.11 billion. In the last trading session, a total of 5.68 million company’s shares exchanged hands. Moreover, sources have it that the company’s total outstanding shares have reached the figures of 186.80 million shares.

News has it Gilead Sciences, Inc. (NASDAQ:GILD) surpassed PepsiCo and went up in the market capitalization category. According to the latest Standard & Poor’s 500 indexes, Gilead Sciences, Inc. (NASDAQ:GILD) took over the number 27 spot that was previously held by PepsiCo, by getting a +1.78%.

Talking about the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), in the trading session, company’s stocks opened at a price of $87.25 and closed at an increased price of $88.68, after hitting the highest price figures of $88.96. The weekly performance shown by company’s stocks was recorded to be 3.97%. The company has a 52 week high of $88.96 and a 52 week low of $54.19, with a market capitalization of $136.58 billion.

On Wednesday, Celgene Corporation (NASDAQ:CELG) disclosed to the public that the company was recently running its tests on a drug, which could be used to treat arthritis; however, the tests remained unsuccessful. Interestingly, this admission of the company’s failure seems to have no effect on the share prices of the company.

In last trading session, company’s stocks started at a price of $84.39 and ended at an increased price of $87.52, with the highest price hitting the figures of $87.91. Moreover, 7.60 million shares of Celgene Corporation (NASDAQ:CELG) exchanged hands, whereas the company’s average trading volume was 5.03 million shares. As far as company’s 52 week high and low figures are concerned, the numbers are reported to be around $7.97 and $4.05 respectively.

According to the Securities and Exchange Commission filing, the Chief Executive Officer of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Jack Lief, recently sold around 40 percent of the company’s stocks. Jack Lief sold a total of 223,525 shares at a mean price of $5.85, which brought the total price to approximately $1.3 million.

On the last trade day, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed its stocks at a price of $4.95. As far as company’s stocks’ institutional and insider ownership figures are concerned, the numbers are reported to be 47.10% and 0.70% respectively. According to the latest reports, the company’s outstanding shares have come to a grand total of 219.66 million shares, whereas 214.40 million shares among them have been floated.

Get Free Updates and Stock Alerts!

*We only send one email per week